R. Ciccia

354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab

C. Celsa, Silvia Contino, Roberto Cannella, R. Ciccia et autres

it, fr (code pays fourni par la source)

305P PHENO-RAG: A modular ensemble large language model framework for hepatocellular carcinoma with patient phenotyping and retrieval augmented generation-guided management

Ciro Celsa, Mauro Giuffrè, G. Di Maria, Roberto Cannella et autres

it, us, fr (code pays fourni par la source)

T.12.9 EARLY HEPATIC DECOMPENSATION IDENTIFIES PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB OR SORAFENIB AT HIGHEST RISK OF DEATH

C. Celsa, G. Cabibbo, S. Battaglia, M. Enea et autres

Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib

G. Cabibbo, C. Celsa, S. Battaglia, M. Enea et autres

it, gb, es, ca, de, us (code pays fourni par la source)

T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK

Ciro Celsa, Giuseppe Cabibbo, R. Ciccia, G. Di Maria et autres

Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network

Ciro Celsa, Giuseppe Cabibbo, R. Ciccia, G. Di Maria et autres

gb, it (code pays fourni par la source)

Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner?

C. Celsa, G. Cabibbo, G.E.M. Rizzo, P. Giuffrida et autres

it (code pays fourni par la source)

OC.08.2 NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: WHO IS THE WINNER?

C. Celsa, G. Cabibbo, G.E.M. Rizzo, P. Giuffrida et autres